Craif

Executive Summary

Craif is a Japanese biotechnology company pioneering non-invasive early cancer detection through its proprietary Bio-AI platform. By analyzing microRNA and other biomarkers in urine, Craif enables screening for cancers that are often diagnosed late, such as pancreatic cancer. The company's lead product, miSignal Urinary Cancer Test, is already commercially available in Japan, marking a significant milestone as one of the first urine-based multi-cancer screening tests on the market. Founded in 2020 and headquartered in Tokyo, Craif has raised $22 million to advance its technology. The company's approach addresses a critical need in oncology: detecting cancers at an early, more treatable stage while reducing the need for invasive procedures. Craif's platform combines molecular biology with artificial intelligence to achieve high sensitivity and specificity, positioning it as a potential leader in the liquid biopsy space. With a growing pipeline targeting additional cancer types and ongoing research collaborations, Craif is well-positioned to expand its footprint in Japan and potentially enter global markets.

Upcoming Catalysts (preview)

• Q2 2026Expansion of miSignal test to pancreatic cancer detection70% success
• Q4 2026Regulatory approval for device in additional Asian markets (e.g., Singapore, South Korea)60% success
• Q3 2026Publication of clinical validation data for multi-cancer screening in peer-reviewed journal80% success